Nuvomedic Canna Consulting Ltd.

09/04/2026

Mental health isn’t just chemistry, it’s regulation - and when that regulation breaks down, symptoms follow. What’s starting to come into focus is how deeply the ECS is involved in that process, not just with major cannabinoids, but with the ones most have barely looked at yet.

In “Therapeutic potential of minor cannabinoids in psychiatric disorders” (2025), researchers step into a lane that’s been overlooked for too long - the role of minor cannabinoids across anxiety, depression, addiction, psychotic disorders, and more. This isn’t a surface-level look, either.

The review pulls together both preclinical and limited clinical data to map how these lesser-known compounds interact with brain signaling and behavior.

What stands out is the scope. Over 100 minor cannabinoids exist, and this paper focuses on how some of them show pharmacological activity that could influence mood, stress response, and reward pathways.

Compounds beyond THC and CBD are interacting with neurotransmitter systems, inflammatory signaling, and the ECS itself in ways that are still being uncovered.

But the paper doesn’t overreach. The findings are promising, not definitive. Most data are preclinical; only one clinical study was included in the review, and variability across studies is high. That’s not a weakness, it’s a signal - we’re early in mapping this system properly.

Here’s the real takeaway. The ECS is already tied to psychiatric function, and cannabinoids, especially the minors, are showing they can interact with that system in meaningful ways. The limitation isn’t potential; it’s the depth of research.

And that’s where this goes next.

-Mike Robinson, Cannabis Patient and Researcher



Study:
https://www.sciencedirect.com/.../pii/S0924977X24007508

09/03/2026

Pain isn’t just what hits the body - it’s also how the brain interprets that signal, weighs it, and turns it into suffering. In “Cannabinoids and Pain: New Insights From Old Molecules” (2018), the authors make a strong case that cannabinoids matter because they do more than dull pain at one point in the chain.

They interact with the machinery of pain signaling, pain amplification, inflammation, and the brain’s perception of pain itself. What makes this one hit harder is that it reaches both the body and the mind.

The review explains that cannabinoid-related analgesia can involve reduced neurotransmitter and neuropeptide release, modulation of postsynaptic excitability, activation of descending inhibitory pain pathways, and reduced neural inflammation.

It also notes that CBD can regulate pain perception through multiple non-cannabinoid targets, while CB1 receptors are located in major pain-processing regions, including the anterior cingulate cortex, amygdala, and prefrontal cortex, areas tied not just to sensation but to how pain feels and how deeply it lands.

The paper also points toward something bigger than simple numbness. In animal work, cannabinoids showed beneficial effects on the affective-emotional and cognitive sides of chronic pain, not just raw nociception.

Clinically, the review says the evidence was moderate overall, with the clearest analgesic signal showing up in chronic neuropathic pain, though the authors were careful about the limitations - short trials, small patient numbers, mixed populations, mixed cannabinoids, and only modest observed effects.

That’s why this review still matters - cannabinoids may help change not only pain intensity, but the way pain is processed and perceived. That’s a different league of conversation, because once you affect pain perception, you’re not just muting a signal - you may be helping reshape the experience of pain itself.

-Mike Robinson, Cannabis Patient and Researcher



Study:
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01259/full

09/03/2026

08/28/2026

Cannabis is the single most versatile herbal remedy, and the most useful plant on Earth. No other single plant contains as wide a range of medically active herbal constituents.

Dr. Ethan Russo

08/27/2026

Infectious disease research has quietly been circling cannabinoids for a different reason than pain or neurology - resistance.

“In “Cannabinoids in Periodontology: Where Are We Now?” (2023), the authors reviewed how cannabinoids may influence periodontal disease through antibacterial activity, immune modulation, and tissue level effects inside the oral environment.

What makes this one stand out is that it pulls cannabinoids into a microbial battlefield. The review highlights that cannabinoids show antibacterial activity, especially against oral pathogens, while also modulating inflammatory responses in periodontal tissues.

That combination matters, because gum disease isn't just bacteria, it's an inflammatory breakdown of tissue driven by both infection and immune response.

The paper also leans into something deeper - homeostasis. Cannabinoid signaling in periodontal tissues may help regulate immune balance and support healing processes, not by wiping everything out, but by influencing how the tissue responds to damage and microbial load.

That's a different model than traditional antibiotics, which are built to kill. Cannabinoids may help shift the environment instead.

The bigger takeaway is where this is heading. As antibiotic resistance keeps climbing, cannabinoids are being looked at as adjunct or alternative strategies, especially in localized environments like the oral cavity.

But the review stays grounded - most of the evidence is still preclinical or early stage, and stronger human data is needed before this becomes standard care.”

-Mike Robinson, Global Cannabinoid Research Center

Study Link: https://www.mdpi.com/2079-6382/12/12/1687

08/27/2026

🌙 In a placebo-controlled clinical trial, oral THC medication reduced the frequency and intensity of trauma-related nightmares in patients with PTSD.

Researchers concluded that dronabinol provided a clinically meaningful benefit with an acceptable safety profile.

🔗 Read more: https://norml.org/news/2026/08/20/clinical-trial-oral-thc-reduces-nightmare-frequency-and-intensity-in-patients-with-post-traumatic-stress/

08/25/2026

Multiple sclerosis has been one of the strongest real world proving grounds for cannabinoid therapeutics because it brings pain, spasticity, sleep disruption, and quality of life into the same disease lane.

“In “Cannabinoids for Treatment of MS Symptoms: State of the Evidence” (2018), the authors reviewed the highest quality data on cannabinoid based formulations for MS and reached a conclusion that still matters - the strongest supportive evidence in neurology was for reducing patient reported spasticity and central pain in multiple sclerosis.

What gives this review weight is that it doesn't blur weak and strong evidence together. The authors report that nabiximols, oral cannabis extract, and synthetic THC were probably effective for reducing patient reported spasticity, and that nabiximols, oral cannabis extract, and synthetic THC were also probably effective for reducing MS related pain.

At the same time, oral cannabis extract and synthetic THC were not found effective for physician administered measures of spasticity, which is an important reminder that patient experience and clinical scoring don't always line up perfectly.

The review also keeps the conversation honest about limits and safety. It notes that cannabinoids in these studies were generally well tolerated and serious adverse events were rare, but it also points to recognized risks including psychosis in at risk individuals, cardiovascular concerns, and cannabinoid hyperemesis syndrome.

The dose picture was not fully settled either, though most participants in the studies discussed used about 20 to 40 mg of THC per day in divided doses.

The bigger takeaway is simple - MS remains one of the clearest conditions where cannabinoid medicine has shown measurable symptom support, especially for spasticity and pain, but the science still demands precision in product type, dosing, and patient selection.

That's where cannabinoid care stops being hype and starts looking like real clinical strategy.”

-Mike Robinson, Global Cannabinoid Research Center



Study Link: https://link.springer.com/article/10.1007/s11910-018-0859-x?utm_source=chatgpt.com

08/24/2026

ENDOCANNABINOIDS: YOUR BODY’S OWN CANNABINOID SIGNALS

Your body makes its own cannabinoids.

Not from cannabis. From you.

“They’re called endocannabinoids—lipid-derived signaling molecules produced by the body. Two of the best studied are anandamide (AEA) and 2-arachidonoylglycerol (2-AG).

Unlike many classical neurotransmitters that are synthesized ahead of time and stored in vesicles waiting for release, endocannabinoids are generally made on demand from lipid precursors in cell membranes.

And here’s where things get especially interesting.

Sometimes the signal runs backward.

We often think about communication between neurons as:

sender → neurotransmitter → receiver

Endocannabinoid signaling can flip that arrangement.

A postsynaptic neuron receiving a signal can produce an endocannabinoid such as 2-AG. It travels back across the synapse and activates CB1 receptors on the presynaptic neuron.

The result can be reduced release of neurotransmitters such as glutamate or GABA.

In effect, the receiving neuron gets to tell the sender:

“Ease up. Turn down the signal.”

This process—called retrograde signaling—allows the brain to dynamically fine-tune synaptic activity.

CB1 and CB2: the major cannabinoid receptors

Two receptors dominate introductory discussions of the endocannabinoid system:

CB1 receptors are especially abundant throughout the brain and nervous system and strongly influence neurotransmitter release.

CB2 receptors have important roles in immune and inflammatory signaling, although they’re also found beyond the immune system.

You’ll sometimes see this simplified to:

CB1 = brain
CB2 = immune system

Useful shorthand perhaps, but biology is often more complex than that.

Both receptors have distributions and functions that extend beyond those neat categories.

What does the ECS actually do?

The endocannabinoid system is sometimes described as a system for maintaining homeostasis—helping biological processes remain within functional ranges.

That’s broadly useful, but it can also be overstated.

The ECS isn’t a master switch independently controlling every organ. It’s better understood as a widespread modulatory signaling system that interacts with many other systems throughout the brain and body.

Endocannabinoid signaling helps fine-tune processes involving:

• stress responses
• pain processing
• appetite & energy balance
• memory & learning
• reward
• sleep & circadian biology
• immune & inflammatory signaling
• synaptic plasticity

And its effects depend heavily on where, when, and under what physiological conditions signaling occurs.

Then the signal has to stop.

Endocannabinoids generally don’t remain active indefinitely.

After doing their job, they’re rapidly taken up and/or metabolized by enzymes.

Two important examples:

FAAH is a major enzyme involved in breaking down anandamide.

MAGL is responsible for much of the degradation of 2-AG.

So instead of simply flooding the nervous system continuously, endocannabinoid signaling can be highly local, dynamic, and temporary.

Produced when needed → signal delivered → signal terminated.

And one important clarification:

Endocannabinoids are NOT THC or CBD.

THC and CBD are phytocannabinoids originating from the cannabis plant.

Anandamide and 2-AG are endocannabinoids produced by your own body.

Endo = within.

The endocannabinoid system existed long before humans discovered cannabis.

Cannabis didn’t create this signaling system. It helped us discover one that was already there.

Educational information only—not medical advice.”

What surprised you most about the endocannabinoid system?

08/23/2026

This one shifts the conversation fast. Most talk about cannabinoids stays at the receptor level, but this pulls it deeper - into the cell’s energy core where real control happens. In the chapter “Cannabinoid modulation of brain mitochondria” (2025), the focus moves straight into how cannabinoids and endocannabinoids interact with mitochondria inside neurons and astrocytes through CB1 signaling.

“Mitochondria aren’t just power generators. They regulate calcium, oxidative stress, and whether a cell survives or breaks down. So when cannabinoids influence mitochondrial tone, they’re not just affecting mood or appetite - they’re shaping how brain cells manage stress, energy, and survival under pressure.

What stands out is that this isn’t a new idea, it’s a refined one. Earlier observations saw mitochondrial effects, but now we’re looking at direct receptor-driven control, especially through mitochondrial CB1 pathways. That ties cannabinoid signaling directly into neuronal output, not just surface-level modulation.

This reinforces something I’ve said for years - cannabinoids don’t replace function, they help restore how the system handles load. When the ECS, our Master Regulator, interfaces with mitochondria, you’re at the intersection of inflammation control, energy production, and neural stability. That’s where balance is either built or lost.”

-Mike Robinson, Global Cannabinoid Research Center

Source: “Cannabinoid modulation of brain mitochondria” (2025)
https://doi.org/10.1016/B978-0-443-13908-6.00008-6